

Herd protection against *Plasmodium falciparum* infections conferred by mass antimalarial drug administrations and the implications for malaria elimination

Daniel M. Parker¹, Sai Thein Than Tun^{2,3}, Lisa J. White^{2,3}, Ladda Kajeechiwa⁴, May Myo Thwin⁴, Jordi Landier⁵, Victor Chaumeau^{3,4,6,7}, Vincent Corbel⁷, Arjen M. Dondorp^{2,3}, Lorenz von Seidlein^{2,3}, Nicholas J. White^{2,3}, Richard J. Maude^{2,3,8}, François H. Nosten^{3,4}

1 Department of Population Health and Disease Prevention; University of California, Irvine; U.S.A.

2 Mahidol-Oxford Tropical Medicine Research Unit; Faculty of Tropical Medicine, Mahidol University; Thailand

3 Centre for Tropical Medicine and Global Health; Nuffield Department of Medicine; University of Oxford, U.K.

4 Shoklo Malaria Research Unit; Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University; Thailand

5 Institut de Recherche pour le Développement (IRD), University of Montpellier; France

6 Centre Hospitalier Universitaire de Montpellier ; France

7 Maladies Infectieuses et Vecteurs, Ecologie, Génétique, Evolution et Contrôle (IRD 224-CNRS 5290 UM1-UM2); Institut de Recherche pour le Développement (IRD), University of Montpellier; France

8 Harvard TH Chan School of Public Health, Harvard University, USA.

*Daniel M. Parker: Dparker1@uci.edu

Sai Thein Than Tun: Sai@tropmedres.ac

Lisa White: Lisa@tropmedres.ac

Ladda Kajeechiwa: Micho@shoklo-unit.com

May Myo Thwin: Myo@shoklo-unit.com

Jordi Landier: Jordi.landier@ird.fr

Victor Chaumeau: Victor@shoklo-unit.com

Vincent Corbel: Vincent.corbel@ird.fr

Arjen Dondorp: Arjen@tropmedres.ac

Lorenz von Seidlein: Lorenz@tropmedres.ac

Nick White: Nickwdt@tropmedres.ac

Richard Maude: Richard@tropmedres.ac

Francois Nosten: Francois@tropmedres.ac

***corresponding author**

Keywords: Plasmodium; elimination; mass drug administration; spatial epidemiology; herd effect

1 **ABSTRACT**

2 The global malaria burden has decreased over the last decade and many nations are attempting
3 elimination. Asymptomatic infections aren't normally diagnosed or treated, posing a major hurdle for
4 elimination efforts. One solution to this problem is mass drug administration (MDA), which is dependent
5 on adequate population participation to disrupt transmission. There is little empirical evidence
6 regarding the necessary threshold level of participation. Here we present a detailed spatiotemporal
7 analysis of malaria episodes and asymptomatic infections in four villages undergoing MDA in Myanmar.
8 Individuals from neighborhoods with high MDA adherence had 90% decreased odds of having a malaria
9 episode post-MDA, regardless of individual participation, suggesting a strong herd effect. High mosquito
10 biting rates, living in a house with someone else with malaria, or having an asymptomatic malaria
11 infection were also predictors of clinical episodes. Spatial clustering of non-adherence to MDA, even in
12 villages with high overall participation, can frustrate elimination efforts.

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33 INTRODUCTION

34 Malaria in the Greater Mekong Subregion (GMS) is heterogeneous in both space and time (Cui, Yan,
35 Sattabongkot, Cao, et al., 2012). Most symptomatic malaria is seasonal and the disease clusters along
36 international borders (Cui, Yan, Sattabongkot, Cao, et al., 2012; Cui, Yan, Sattabongkot, Chen, et al.,
37 2012; Parker, Carrara, Pukrittayakamee, Mcgready, & Nosten, 2015). All of the nations of the GMS have
38 committed to eliminating malaria by 2030 (WHO, 2016) and cases of *Plasmodium falciparum* malaria
39 have been decreasing over the last several decades. However, parasites are developing resistance to the
40 first line of antimalarials (Phyo et al., 2016), presenting a public health emergency in the current
41 absence of appropriate replacement therapies. One proposed solution to this problem is the elimination
42 of *P. falciparum* parasites while prevalence is low and while combination therapies remain effective in
43 clearing low density infections (von Seidlein & Dondorp, 2015).

44 The foundation of malaria elimination programs is the provision of access to early diagnosis and
45 treatment (EDT) to all affected communities (Jordi Landier et al., 2016). Throughout the GMS this has
46 been facilitated through programs which employ village or community health workers (Carrara et al.,
47 2006); a system that has existed in parts of the GMS for over 50 years (especially in Thailand, Vietnam
48 and China) (Kauffman & Myers, 1997; Lehmann & Sanders, 2007; Zhang & Unschuld, 2008). Infected and
49 symptomatic individuals who quickly seek and receive early diagnosis and treatment have reduced
50 infectious periods, leading to a reduction in transmission.

51 Recent work from several different parts of the GMS found several populations with high asymptomatic
52 malaria prevalence (Imwong et al., 2015). Asymptomatic individuals are not treated and serve as a
53 reservoir for persistence of malaria in the region even in the presence of strong healthcare systems.
54 Therefore, another key tool in the elimination portfolio is targeted mass drug administration (MDA).
55 MDA includes the administration of antimalarials to all individuals in a targeted population, in this case
56 in communities that have high malaria prevalence (von Seidlein & Dondorp, 2015). There is likely to be a
57 critical threshold for MDA coverage, below which the reduction of the parasite reservoir is not sufficient
58 to halt ongoing transmission. However, there is little empirical evidence of such coverage effects.

59 Here we describe geographic and epidemiologic patterns of clinical and subclinical *P. falciparum* and *P.*
60 *vivax* infections in villages receiving targeted MDA. We investigate associations between heterogeneous
61 adherence to MDA, mosquito vector biting rates, asymptomatic infections, and clinical malaria episodes.
62 To our knowledge this is the first subvillage level spatiotemporal analysis of malaria incidence and
63 prevalence from an any MDA study.

64 METHODS

65 *Study location and design*

66 The study site consisted of four villages (KNH, TPN, HKT, and TOT) along the Myanmar-Thailand border,
67 in Kayin (Karen) State, Myanmar (Jordi Landier et al., 2017). The villages were selected based on malaria
68 prevalence estimates from a preliminary survey in the area (Imwong et al., 2015) and were part of a
69 MDA pilot study (Jordi Landier et al., 2017). The northernmost village is approximately 105 km from the
70 southernmost and the two closest villages, KNH and TPN are within 10km of each other (**Figure 1**). The
71 study was conducted from May 2013 through June 2015.

72 A full population census was completed in each of the four study villages at baseline May – June 2013.
73 Everyone enumerated in the census was given a unique identification code. Geographic coordinates
74 were collected for all houses in the four study villages and a unique identification code was assigned to
75 each house. All individuals were then linked to their respective houses.

76 Blood surveys were conducted at baseline in each village, aiming to screen all individuals above an age
77 of 9 months. Venous blood (3mL) was drawn from each participant, transported to a central laboratory
78 and analyzed using a highly sensitive quantitative PCR (uPCR) assay with a limit of detection of 22
79 parasites per mL. (Imwong et al., 2014). Subclinical infections detected through these blood screenings
80 are hereafter referred to as uPCR-detected “infections” of either *P. falciparum* or *P. vivax*. Most of these
81 infections (86%) were asymptomatic (J. Landier et al., 2017).

82 A community-based malaria clinic (malaria post or MP) was established in each village at the beginning
83 of the project. Villagers were trained to diagnose malaria using rapid diagnostic tests (RDTs) and to treat
84 RDT positive infections with dose-based on weight and age. The ID code of each participant who self-
85 presented at the MP was recorded, along with RDT results and these cases are hereafter referred to as
86 clinical malaria episodes of either *P. falciparum* or *P. vivax*. Malaria episodes were treated with
87 dihydroartemisinin-piperaquine (DHA+P) for *P. falciparum* and chloroquine for *P. vivax*. Radical cure for
88 *P. vivax* was not provided because the absence of G6PD tests required to prevent hemolysis in G6PDd
89 individuals (Bancone et al., 2014; Chu et al., 2017).

90 MDAs were initially conducted in four villages selected based on *P. falciparum* prevalence surveys (using
91 uPCR) in the region. MDAs were conducted in two villages at the beginning of the study and extended to
92 the two control villages beginning in M9. Restricted randomization was used to decide which village
93 received early or deferred MDA. MDA consisted of 3 days of DHA+P, with a single low dose of
94 primaquine on the third day, repeated over three months (M0, M1, M2 for the first group and M9, M10,
95 M11 for the control group). Follow-up blood surveys were conducted in each village every third month
96 after M0 until M18. A final full blood survey was completed in each village at M24.

97 Mosquitoes were collected monthly using human landing catches to estimate the human biting rate
98 (HBR). Mosquito catching teams were based at 5 sites (both indoors and outdoors) within each of the
99 four study villages (total of 20 catch sites) for 5 consecutive nights during the study period M0 through
100 M20. Mosquitoes were caught using glass tubes and later identified morphologically (Ya-umphan et al.,
101 2016).

102 The locations of MPs, catch sites and village houses are indicated in Figure 1.

103 **ANALYSIS**

104 **Variables**

105 All individuals recorded in the census with a house address in the four study villages were included in
106 this analysis.

107 The data were aggregated into one month time steps and individuals were coded with a “1” for any
108 month in which they presented at the village MP and were diagnosed with a *P. falciparum* or *P. vivax*
109 infection. Likewise, individuals who did not have a clinical episode within a given month were coded
110 with a “0” for that respective month. Individuals who were ever diagnosed with a clinical episode or

111 uPCR detected infection (either *P. falciparum* or *P. vivax*) were likewise coded as a “1” for analyses of
112 having ever been detected by uPCR for an infection or having ever had a clinical episode during the
113 study period.

114 Individual level predictor variables included age group, gender, infection status (not infected = 0;
115 infected =1) and adherence to MDA (number of doses taken). Household level predictor variables
116 included a binary variable for whether or not another household member had a clinical episode and
117 whether or not another household member had a uPCR-detected infection.

118 The human biting rate (HBR) for primary vectors (*Anopheles minimus s.l.*, *An. maculatus s.l.*, and *An.*
119 *dirus s.l.*) was calculated for each month and for each catch site. HBR values were then attributed to
120 individuals based on their house location, assigning the HBR from the catch site that was geographically
121 closest to each house.

122 Neighborhood MDA adherence was calculated as the proportion of people who took no rounds of MDA
123 within 100 meters radius of each house in the study population. This proportion was calculated for each
124 house in the study villages and non-adherence proportions were then attributed to individuals based on
125 the house to which they were attributed.

126 Both HBR and neighborhood MDA variables were operationalized as tertiles (lowest third, middle third,
127 highest third, indicated in **Supplementary Table 1**).

128 **Exploratory spatial and temporal analyses**

129 All predictor variables were explored in bivariate analyses. Unadjusted odds ratios were calculated for
130 binary predictors and Wilcoxon rank sum tests were calculated for continuous variables. Cumulative
131 hazards curves were used to analyze temporal patterns in infections.

132 uPCR-detected infections (from surveys) and clinical episodes (from the MPs) were mapped at the house
133 level across time. Maps were created for each village and each survey time point (M0 – M24), with
134 clinical episodes aggregated to align with surveys (i.e. M1, M2 and M3 aggregated into M3).

135 The standard distance deviation (SDD), a two-dimensional version of a normal standard deviation, was
136 used to visually analyze the distribution of clinical *P. falciparum* episodes for each time point in the one
137 village with sufficient *P. falciparum* infections (TOT). SDD are calculated by finding the mean center of all
138 points, weighted by the number of clinical episodes. The SDD is the average distance from mean center
139 (for both the x and the y plane) for all weighted points and is represented by a circular map layer
140 centered on the weighted mean with the standard distance as radius. One SDD was calculated,
141 corresponding to approximately 68% of all points falling inside of the resulting circle.

142 Scan statistics were used to test for clustering of uPCR-detected infections (*P. falciparum* and *P. vivax*)
143 across survey months; clinical episodes (*P. falciparum* and *P. vivax*) across all months of the study period
144 and MDA non-participation (operationalized as the number of individuals who took none of the three
145 rounds of MDA). The scan statistics used a moving window (a circle) that centered on each point in the
146 village, testing for the relative risk of cases given a population size within the circle in comparison to the
147 risk outside of the circle. The circle increased in size until it included half of the population and then
148 moved to the next geographic reference point. For Plasmodium infections and malaria episodes the

149 space-time discrete Poisson model was used whereas for MDA participation a purely spatial Poisson
150 model was used (Kulldorff, 1997) (as MDAs were completed within a 3 month time period).

151 **Logistic regression**

152 Mixed effects logistic regressions were used to calculate model adjusted odds ratios (AOR) and
153 confidence intervals for individual, household and neighborhood level risk factors (variables above) for
154 clinical episodes (*P. falciparum* or *P. vivax*) after MDA. These regressions included a random intercept to
155 account for repeated measures within individuals across the study period.

156 Most *P. falciparum* infections post-MDA occurred in a single village (TOT), therefore regressions for *P.*
157 *falciparum* infections post-MDA were based on this village alone whereas regressions for *P. vivax*
158 included all 4 study villages. A final set of regressions looked at the odds of *P. falciparum* or *P. vivax*
159 infection being detected by uPCR after MDA.

160 **Software**

161 Exploratory statistics and regressions were calculated using R (version 3.4.3; <https://cran.r-project.org/>)
162 and the “epiR”, “lme4”, and “survival” packages. All maps were created using ArcGIS 10.5
163 (<https://www.arcgis.com/>). Exploratory spatial data analysis was conducted using ArcGIS 10.5 and
164 SatScan v9.5 (<https://www.satscan.org/>). The neighborhood participation variable was created using
165 ArcGIS and the Python programming language (version 3.5.2; <https://www.python.org/>).

166 **Ethics approval**

167 This project was approved by the Oxford Tropical Research Ethics Committee (OxTREC: 1015-13; April
168 29, 2013) and the Tak Province Community Ethics Advisory Board (T-CAB).

169 **RESULTS**

170 3229 villagers (1689 male) were included in this study. During the study period 80 study participants
171 were diagnosed with clinical *P. falciparum* and 216 with clinical *P. vivax*. 201 and 611 participants were
172 found to have *P. falciparum* or *P. vivax* infections respectively by uPCR and 325 uPCR positive
173 participants had Plasmodium infections not identifiable at the species level. Infections that were not
174 identifiable at the species level were not included in these analyses. Total numbers of clinical episodes
175 and uPCR-detected infections were higher than the total number of infected individuals because some
176 participants had multiple infections.

177 The majority of clinical *P. falciparum* infections occurred in one of the study villages (TOT). 66 out of the
178 80 participants who had a clinical *P.falciparum* case were from TOT village (3 from HKT, 7 from TPN and
179 4 from KNH).

180 39 (49%) of the participants who had a clinical *P. falciparum* episode lived in a house with someone who
181 had a clinical *P. falciparum* episode (unadjusted odds ratio (UOR): 8.1; CI: 5.1 – 12.7). 35 (44%) of the
182 participants who had a clinical *P. falciparum* episode lived in a house with someone who had a uPCR-
183 detected *P. falciparum* infection during the study period (UOR: 1.6; CI: 1.0 – 2.4).

184 11 of the 80 participants (14%) who had a clinical *P. falciparum* infection during the study period had
185 repeated clinical episodes. *P. falciparum* and *P. vivax* infections were more prevalent in males than
186 females (UOR: 2.0; CI: 1.5 – 2.8 for *P. falciparum* and UOR: 1.7; CI: 1.4 – 2.0 for *P. vivax*).

187 **Spatiotemporal patterns in uPCR-detected infections, clinical episodes and MDA adherence**

188 *P. falciparum* and *P. vivax* infections were detected in all villages at baseline (**Figures 2 and 3**). These
189 infections were significantly reduced following MDA in all villages. The prevalence of *P. falciparum*
190 infections had reduced in two villages (villages TPN and HKT) prior to MDA. *P. vivax* infections returned
191 in subsequent months in most villages (as expected given that radical cure was not provided), with the
192 exception of village TPN.

193 There were statistically significant clusters of uPCR-detected *P. falciparum* infections in each village at
194 baseline but subsequently no significant clusters were detected (**Figure 2**). Clusters of clinical *P.*
195 *falciparum* episodes occurred in two villages (KNH and TOT). The cluster in KNH occurred from M5
196 through M7 but included only four episodes. There were two separate clusters in village TOT. A cluster
197 in the western portion of the village began in M12 and lasted until M18 (with a total of 35 episodes). A
198 single-house cluster occurred in the eastern portion of the village (M15 through M18) with 5 episodes
199 among 4 house members (2 in a 10 yo male, 1 in a 48 yo male, 1 in a 16 yo male, and 1 in a 48 year old
200 female).

201 *P. vivax* infections were widespread throughout the study villages at baseline but no spatial clustering
202 pattern was detected at M0 (**Figure 3**). Village HKT had a cluster at M3; village KNH had one persistent
203 cluster from M9 through M18; and village TOT had two clusters at M24 (**Figure 2**). Clusters of clinical *P.*
204 *vivax* episodes also lingered in village KNH (M3 through M14 (17 episodes) and then M12 through M24
205 (6 episodes)) and in village TOT (M12 through M21 (31 episodes) and M19 through M23 (18 episodes)).
206 There was a cluster of clinical *P. vivax* episodes in village HKT during M23 and M24 (including 23
207 episodes).

208 There were significant clusters of non-participation in the MDAs in three of the study villages (TPN, HKT
209 and TOT (**Supplementary Figure 1**)). The non-participation cluster in TOT made up a large portion of the
210 western part of the village and included 115 individuals not participating in the MDA. The non-
211 participation clusters in HKT and TPN included 206 and 15 individuals respectively.

212 Sporadic clinical *P. falciparum* episodes occurred in village TOT from M6 to M9, followed by a small
213 outbreak beginning in M13 (**Figure 2**). The first clinical *P. falciparum* episodes during this outbreak
214 occurred among villagers who lived in the cluster of non-MDA participation (**Figure 4**). By M24 the
215 clinical episodes had spread through much of the village (**Figure 4**).

216 Cumulative hazards plots of clinical *P. falciparum* episodes in village TOT illustrate the temporal patterns
217 in infections according to neighborhood MDA adherence and household clustering (**Figure 5A**). The
218 proportion of individuals who had acquired a clinical *P. falciparum* episode began consistently increasing
219 in M12 for those living in either low or mid MDA adherence neighborhoods. *P. falciparum* episodes
220 among high MDA adherence neighborhoods began increasing approximately one month after the
221 increase in low adherence neighborhoods but never reached the level experienced in either mid or low
222 MDA adherence neighborhoods. 4.4% of all individuals in high MDA adherence neighborhoods had at
223 least one clinical *P. falciparum* episode by the end of the study period, in comparison to 7.6% in mid and
224 9.6% in low MDA adherence neighborhoods (log-rank test p-value = 0.0485; **Figure 5A**).

225 Clinical *P. falciparum* episodes also clustered within houses. Beginning in M6, the proportion of
226 individuals who acquired *P. falciparum* episodes was higher among those who lived in a house with

227 someone else who had a clinical *P. falciparum* episode. The overall proportion of people who acquired a
228 clinical *P. falciparum* episode was consistently higher throughout the study period among those who
229 lived with someone else who had a clinical *P. falciparum* episode (log-rank test p-value < 0.0001; **Figure**
230 **5B**).

231 The increase in clinical *P. falciparum* episodes in M13 coincided with an increase in HBR in village TOT
232 (**Figure 5C**).

233 **Longitudinal analysis of clinical *P. falciparum* and *P. vivax* episodes**

234 Clinical *P. falciparum* episodes after MDA in village TOT were most likely to occur among 5 to 14 year
235 olds (AOR: 3.0; CI: 1.2 – 7.9) and participants who lived in a house with someone else who had a clinical
236 *P. falciparum* episode during the same month (AOR: 4.2; CI: 2.1 – 8.6) (**Table 3**). Living in a neighborhood
237 with a high proportion of adherence to MDA had a protective effect, being associated with a 90%
238 decrease in the odds of having a clinical episode (AOR: 0.1; CI: 0.01 – 0.51) compared to people who
239 lived in low adherence neighborhoods (**Table 1**). These effects remained after controlling for time.

240 Living in part of the village with a high HBR was also associated with increased odds of *P. falciparum*
241 infection. Individuals who lived in high HBR portions of the village had over two times the odds of
242 acquiring a clinical episode (AOR: 2.3; CI: 1.2 – 4.5) when compared to those who lived in parts of the
243 village with a low HBR (**Table 3**).

244 Clinical *P. vivax* episodes also exhibited household clustering. Individuals who lived in a house with
245 someone who had a clinical *P. vivax* episode during the same month had over 5 times the odds of having
246 a clinical *P. vivax* episode when compared to those who did not live in a house with someone who had a
247 clinical *P. vivax* episode (AOR: 5.8; CI: 3.4 – 9.9) (**Table 3**). Living in part of a village with mid or high HBR
248 was also associated with an increased odds of *P. vivax* infection (mid HBR – AOR: 1.6; CI: 1.1 – 2.4; high
249 HBR – AOR: 1.6; CI: 1.1 – 2.4).

250 **Logistic regression for odds of having a uPCR-diagnosed infection after MDA**

251 The strongest predictor of having a uPCR detected *P. falciparum* infection after MDA was also having a
252 clinical *P. falciparum* episode after MDA (AOR: 4.6; CI: 1.8 – 11.1) (**Table 2**). uPCR detected *P. vivax*
253 infections occurred mostly in older children (AOR: 2.6; CI: 1.7 – 4.1), adults (AOR: 2.3; CI: 1.6 – 3.6) and
254 males (AOR: 1.8; CI: 1.4 – 2.2) (**Table 2**). Individuals who had a clinical *P. vivax* episode after MDA had
255 2.7 times the odds (CI: 1.9 – 3.9) and individuals who lived in a house with someone else with a uPCR
256 detected *P. vivax* infection had 1.5 times the odds (CI: 1.2 – 2.0) of also having a uPCR detected infection
257 after MDA (**Table 2**).

258 **DISCUSSION**

259 The primary goal of targeted MDA in the study villages was to reduce the prevalence of uPCR-detected
260 *P. falciparum*. There was also a significant impact on the incidence of clinical *P. falciparum* episodes, also
261 as a result of MDA. This analysis shows that post-MDA clinical *P. falciparum* infections in one village, TOT
262 exhibited strong spatiotemporal clustering within houses in low MDA-adherence neighborhoods and
263 within portions of the village with high HBR.

264 There was no protective effect beyond the prophylactic period after taking MDA at the individual level,
265 but there was a group level effect suggesting a level of herd protection. Those who lived in

266 neighborhoods with high participation in MDA had a reduced risk of becoming infected, regardless of
267 their individual participation in MDA. This protective effect was most pronounced in the rainy season
268 following MDA (**Figure 4**) and corresponded to a surge in vector activity (**Figure 5C**). Once the *P.*
269 *falciparum* outbreak began, there was a lag of approximately 1 month between the onset of clinical
270 episodes in neighborhoods with mid and low MDA adherence and the spread to neighborhoods with
271 high MDA adherence (**Figure 5A**). However, neighborhoods with high MDA adherence never
272 experienced the same levels of infection as those with mid or low MDA adherence (**Figure 5A, Table 1**).
273 To our knowledge, this is the first documentation of a herd effect conferred of MDA for *P. falciparum*
274 malaria.

275 HBR was also strongly predictive of clinical *P. falciparum* episodes in village TOT. The increase in clinical
276 *P. falciparum* episodes post-MDA occurred both in areas where MDA adherence was poor and where
277 HBR was high. HBR also peaked in one other village (HKT) at the same time as in village TOT (**Figure 5C**),
278 but occurred in the absence of a detectable parasite reservoir (**Figure 2**) and the HBR did not persist at
279 high levels. Evidence suggests that the MP in TOT was not functioning well in the first year of the study
280 (reported in (J. Landier et al., 2017)) and this influenced the outbreak in TOT.

281 The combination of a persisting parasite reservoir and persistently high HBR (from M13 – M18) in TOT
282 likely explains the drastically different results between the study villages with regard to *P.falciparum*
283 malaria elimination (**Figure 2**). A better functioning MP in TOT would have reduced the size of the
284 outbreak.

285 Post-MDA clinical *P. vivax* episodes exhibited spatiotemporal clustering within houses and within areas
286 with mid to high levels of HBR. uPCR-detected *P. vivax* infections also clustered within houses. While
287 there was an immediate reduction in blood-stage *P. vivax* following MDA (evident in **Figure 3**) there was
288 no overall effect of MDA on the risk of subsequent clinical episodes or uPCR-detected infections over the
289 entire surveillance period (Chaumeau et al 2018; not yet published).

290 Clinical *P. vivax* episodes occurred more commonly among younger age groups while uPCR-detected
291 infections occurred more commonly among adults. This pattern was previously described in Thai-Burma
292 border populations over two decades ago (Luxemburger et al., 1996) and is likely the result of some
293 level of acquired immunity to *P. vivax* infections with time. Both adults and children are exposed to
294 similar levels of *P. vivax* transmission, yet in children the infection is more likely to result in clinical
295 symptoms whereas in adults, many of the infections are likely to become or remain asymptomatic.

296 Clustering of *P. falciparum* infections across houses occurred for limited periods of time only prior to
297 MDA (**Figure 2**). Clustering of *P. vivax* across houses persisted across time before and after MDA (**Figure**
298 **3**). Overlapping clusters of clinical *P. vivax* episodes and uPCR-diagnosed *P. vivax* infections were
299 observed in KNH (M9 through M15) and TOT (M24). There were overlapping clusters of clinical *P. vivax*
300 episodes and clinical *P. falciparum* episodes in village KNH (M5 – M7) and village TOT (M12 – M18). The
301 spatiotemporal clustering patterns of both *P. falciparum* and *P. vivax* suggest that interventions such as
302 reactive case detection would have resulted in the detection of extra cases (of both clinical and uPCR-
303 detected *P. falciparum* and *P. vivax*) when searching within houses and occasionally in neighboring
304 houses, but these would have only been a small proportion of all infections within the villages (Parker et
305 al., 2016) and would not have halted transmission. Conversely, community based EDT and MDA with
306 high participation, targeted at the village scale or larger, appear effective at reducing prevalence,
307 incidence and transmission of *P. falciparum* (Jordi Landier et al., 2018).

308 Individuals with clinical episodes of both *P. falciparum* and *P. vivax* were frequently, diagnosed (either
309 before or after experiencing an episode) with asymptomatic infections during blood screenings. The
310 study did not genotype the infections. In this low transmission setting at least a proportion of these
311 associated clinical episodes and uPCR detected infections are likely to have been the same parasite
312 strain, suggestive of long-term carriage of both *P. falciparum* and *P. vivax*. This is supported by a large
313 Vietnamese cohort study, showing that 20% of asymptomatic *P. falciparum* carriers and 59% of *P. vivax*
314 carriers carry their parasitaemia for 4 months or longer (Chen et al., 2016; Nguyen et al., 2018). The
315 observation that *P. falciparum* and *P. vivax* parasite densities oscillate during long-term Plasmodium
316 carriage suggests that gametocytaemia might also occur in waves, at some point in time sufficient to
317 transmit to a suitable vector. If such infections remain asymptomatic, they are unlikely to be diagnosed
318 and treated through standard early diagnosis and treatment (EDT) approaches. Active approaches for
319 detecting and treating these infections, such as targeted MDA or mass screen and treat, are necessary.

320 There are several limitations to this work. Individuals who did not participate in MDA also did not
321 participate in blood screenings immediately after MDA (i.e. M3 in village TOT). uPCR detected infections
322 are therefore likely to be underdiagnosed for these individuals. There is also evidence of a poorly
323 functioning MP in this village, which could have meant undiagnosed (and therefore unrecorded) clinical
324 episodes, especially during the beginning of the study. Finally, some infections are likely to be acquired
325 outside of the village, leading to complex spatial patterns in infections that are mapped at the house
326 level. Within household clustering can be the result of within house transmission, or shared exposure
327 among household members.

328 **CONCLUSION**

329 These data suggest that poor MDA adherence in the presence of a significant parasite reservoir and
330 sufficient vector activity, can lead to resurgence of malaria in a matter of months after reduced
331 transmission due to MDA (**Figure 5A**). This is especially true in a setting with a poorly functioning
332 diagnosis and treatment center. Conversely, high coverage of MDA in a population can confer benefits
333 long after the prophylactic period has ended – most likely as a result of clearing the parasite reservoir
334 (**Table 1, Figure 5A**). Community engagement to maximize community participation, is crucial for MDA
335 success (Kajeechiwa et al., 2017) and villages or portions of villages with poor adherence present
336 persistent challenges to elimination efforts.

337 **ACKNOWLEDGEMENTS**

338 We would like to thank the study communities in Kayin State, Myanmar for their participation, support
339 and acceptance. We would also like to acknowledge the many staff members at Shoklo Malaria
340 Research Unit and the Mahidol-Oxford Tropical Medicine Research Unit who made this project possible.
341 This study is part of the larger “Targeted Chemo-elimination (TCE) of Malaria (TME)” project, which is
342 registered at ClinicalTrials.gov: NCT01872702 (<https://clinicaltrials.gov/ct2/show/NCT01872702>).
343 Funding for the TME project was obtained from Wellcome Trust (101148/Z/13/Z) to Prof. Nicholas J.
344 White and the Bill and Melinda Gates Foundation (OPP1081420) to Prof. Arjen M. Dondorp. Sai Thein
345 Than Tun is supported by the Wellcome Trust (grant no. 205240/Z/16/Z).

346 **COMPETING INTERESTS**

347 We declare that we have no competing interests.

348 REFERENCES


349

- 350 Bancone, G., Chu, C. S., Somsakchaicharoen, R., Chowwiwat, N., Parker, D. M., Charunwatthana, P., ...
351 Nosten, F. H. (2014). Characterization of G6PD Genotypes and Phenotypes on the Northwestern
352 Thailand-Myanmar Border. *PLoS One*, 1–11. <https://doi.org/10.1371/journal.pone.0116063>
- 353 Carrara, V. I., Sirilak, S., Thonglairuam, J., Rojanawatsirivet, C., Proux, S., Gilbos, V., ... Nosten, F. (2006).
354 Deployment of early diagnosis and mefloquine-artesunate treatment of falciparum malaria in
355 Thailand: the Tak Malaria Initiative. *PLoS Medicine*, 3(6), e183.
356 <https://doi.org/10.1371/journal.pmed.0030183>
- 357 Chen, I., Clarke, S. E., Gosling, R., Hamainza, B., Killeen, G., Magill, A., ... Riley, E. M. (2016).
358 “Asymptomatic” Malaria: A Chronic and Debilitating Infection That Should Be Treated. *PLoS*
359 *Medicine*, 13(1), 1–11. <https://doi.org/10.1371/journal.pmed.1001942>
- 360 Chu, C. S., Bancone, G., Moore, K. A., Win, H. H., Thitipanawan, N., Po, C., ... White, N. J. (2017).
361 Haemolysis in G6PD Heterozygous Females Treated with Primaquine for Plasmodium vivax Malaria:
362 A Nested Cohort in a Trial of Radical Curative Regimens. *PLOS Medicine*, 14(2), e1002224.
363 <https://doi.org/10.1371/journal.pmed.1002224>
- 364 Cui, L., Yan, G., Sattabongkot, J., Cao, Y., Chen, B., Chen, X., ... Zhou, G. (2012). Malaria in the Greater
365 Mekong Subregion: Heterogeneity and complexity. *Acta Tropica*, 121(3), 227–239.
366 <https://doi.org/10.1016/j.actatropica.2011.02.016>
- 367 Cui, L., Yan, G., Sattabongkot, J., Chen, B., Cao, Y., Fan, Q., ... Zhou, G. (2012). Challenges and prospects
368 for malaria elimination in the Greater Mekong Subregion. *Acta Tropica*, 121(3), 240–5.
369 <https://doi.org/10.1016/j.actatropica.2011.04.006>
- 370 Imwong, M., Hanchana, S., Malleret, B., Rénia, L., Day, N. P. J., Dondorp, A., ... White, N. J. (2014). High-
371 throughput ultrasensitive molecular techniques for quantifying low-density malaria parasitemias.
372 *Journal of Clinical Microbiology*, 52(9), 3303–3309. <https://doi.org/10.1128/JCM.01057-14>
- 373 Imwong, M., Nguyen, T. N., Tripura, R., Peto, T. J., Lee, S. J., Lwin, K. M., ... Nosten, F. (2015). The
374 epidemiology of subclinical malaria infections in South-East Asia: findings from cross-sectional
375 surveys in Thailand–Myanmar border areas, Cambodia, and Vietnam. *Malaria Journal*, 14(1), 381.
376 <https://doi.org/10.1186/s12936-015-0906-x>
- 377 Kajechiwa, L., Thwin, M. M., Nosten, S., Tun, S. W., Parker, D., Von Seidlein, L., ... Cheah, P. Y. (2017).
378 Community engagement for the rapid elimination of malaria: the case of Kayin State, Myanmar.
379 *Wellcome Open Research*, 2. <https://doi.org/10.12688/wellcomeopenres.12051.1>
- 380 Kauffman, K. S., & Myers, D. H. (1997). The changing role of village health volunteers in Northeast
381 Thailand: an ethnographic field study. *Int J Nurs Stud*, 34(4), 249–255.
- 382 Kulldorff, M. (1997). A spatial scan statistic. *Communications in Statistics: Theory and Methods*, 26,
383 1481–1496.
- 384 Landier, J., Kajechiwa, L., Thwin, M. M., Parker, D. M., Chaumeau, V., Wiladphaingern, J., ... Nosten, F.
385 H. (2017). Safety and effectiveness of mass drug administration to accelerate elimination of
386 artemisinin-resistant falciparum malaria: A pilot trial in four villages of Eastern Myanmar.
387 *Wellcome Open Research*, 2. <https://doi.org/10.12688/wellcomeopenres.12240.1>

- 388 Landier, J., Kajeewiwa, L., Thwin, M. M., Parker, D. M., Chaumeau, V., Wiladphaingern, J., ... Nosten, F.
389 H. (2017). Safety and effectiveness of mass drug administration to accelerate elimination of
390 artemisinin-resistant falciparum malaria: A pilot trial in four villages of Eastern Myanmar [version
391 1; referees: awaiting peer review]. *Wellcome Open Research*, 2(81).
- 392 Landier, J., Parker, D. M., Thu, A. M., Carrara, V. I., Lwin, K. M., Bonnington, C. A., ... Nosten, F. H. (2016).
393 The role of early detection and treatment in malaria elimination. *Malar J*, 15.
394 <https://doi.org/10.1186/s12936-016-1399-y>
- 395 Landier, J., Parker, D. M., Thu, A. M., Lwin, K. M., Delmas, G., Nosten, F. H., ... Force, T. (2018). Effect of
396 generalised access to early diagnosis and treatment and targeted mass drug administration on
397 Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional
398 elimination programme. *The Lancet*, 6736(18), 1–11. <https://doi.org/S014067361830792X>
- 399 Lehmann, U., & Sanders, D. (2007). Community health workers: What do we know about them?,
400 (January). Retrieved from http://www.who.int/hrh/documents/community_health_workers.pdf
- 401 Luxemburger, C., Thway, K. L., White, N. J., Webster, H. K., Kyle, D. E., Maclankirri, L., ... Nosten, F.
402 (1996). The epidemiology of malaria in a Karen population on the western border of Thailand.
403 *Trans R Soc Trop Med Hyg*, 90, 105–111.
- 404 Nguyen, T., Seidlein, L. Von, Nguyen, T., Truong, P., Hung, S. Do, Pham, H., & Nguyen, T. (2018). The
405 persistence and oscillations of submicroscopic Plasmodium falciparum and Plasmodium vivax
406 infections over time in Vietnam : an open cohort study. *The Lancet Infectious Diseases*, 3099(18),
407 1–8. [https://doi.org/10.1016/S1473-3099\(18\)30046-X](https://doi.org/10.1016/S1473-3099(18)30046-X)
- 408 Parker, D. M., Carrara, V. I., Pukrittayakamee, S., Mcgreedy, R., & Nosten, F. H. (2015). Malaria ecology
409 along the Thailand– Myanmar border. *Malaria Journal*, 14. <https://doi.org/10.1186/s12936-015-0921-y>
- 411 Parker, D. M., Landier, J., von Seidlein, L., Dondorp, A., White, L., Hanboonkunupakarn, B., ... Nosten, F.
412 H. (2016). Limitations of malaria reactive case detection in an area of low and unstable
413 transmission on the Myanmar–Thailand border. *Malaria Journal*, 15(1), 571.
414 <https://doi.org/10.1186/s12936-016-1631-9>
- 415 Phyto, A. P., Ashley, E. A., Anderson, T. J. C., Bozdech, Z., Carrara, V. I., Sriprawat, K., ... Nosten, F. (2016).
416 Declining Efficacy of Artemisinin Combination Therapy Against P. Falciparum Malaria on the Thai–
417 Myanmar Border (2003 – 2013): The Role of Parasite Genetic Factors. *Clinical Infectious Diseases*,
418 63. <https://doi.org/10.1093/cid/ciw388>
- 419 von Seidlein, L., & Dondorp, A. (2015). Fighting fire with fire: mass antimalarial drug administrations in
420 an era of antimalarial resistance. *Expert Review of Anti-Infective Therapy*, 13(6), 715–730.
- 421 WHO. (2016). Eliminating malaria in the Greater Mekong Subregion: united to end a deadly disease.
422 World Health Organization. Retrieved from
423 <http://apps.who.int/iris/bitstream/10665/251668/1/WHO-HTM-GMP-2016.12-eng.pdf?ua=1>
- 424 Ya-umphan, P., Cerqueria, D., Parker, D. M., Cottrell, G., Poinsignon, A., Remoue, F., ... Corbel, V. (2016).
425 Anopheles salivary biomarker to assess malaria transmission risk along the Thailand-Myanmar
426 border. *Journal of Infectious Diseases*, first publ.
- 427 Zhang, D., & Unschuld, P. U. (2008). China's barefoot doctor: past, present, and future. *The Lancet*,
428 372(9653), 1865–1867. [https://doi.org/10.1016/S0140-6736\(08\)61355-0](https://doi.org/10.1016/S0140-6736(08)61355-0)

429

430 **Figure 1:** Map indicating the locations of the study villages along the Myanmar-Thailand border; and the
431 distribution of houses, mosquito catch sites and malaria posts within study sites.



432

433

434

435

436

437

438

439

440

441

442

Figure 2: Clinical *P. falciparum* episodes (yellow square points) and uPCR-detected *P. falciparum* infections (blue dots) at house level over time for each of the four study villages. Statistically significant clusters (detected using SaTScan) are indicated for both clinical episodes (underlying yellow circles) and uPCR-detected infections (underlying blue circles).




Figure 3: Clinical *P. vivax* episodes (yellow square points) and uPCR-detected *P. vivax* infections (blue dots) at house level over time for each of the four study villages. Statistically significant clusters (detected using SaTScan) are indicated for both clinical episodes (underlying yellow circles) and PCR-detected infections (underlying blue circles).




Figure 4: Spatiotemporal distribution of clinical *P. falciparum* episodes (yellow square points), uPCR detected *P. falciparum* infections (blue dots), and a cluster of non-participation in MDA (grey circle/ochre border, detected using SatScan). Season is indicated by colored squares in the top right corner of each map. A measure of the spread of clinical *P. falciparum* cases is given by the standard distance deviation (“SD”), indicated by the hollow circle with dark grey outline. One standard deviation is shown, indicating that roughly 68% of all cases lie inside of the circle. Approximately 6 months post-MDA (M9), clinical infections began in the westernmost portion of the village. The distribution of these cases through month 15 corresponds with the cluster of non-MDA participation (indicated by the grey circle in M3). By M24 the cases extended throughout much of the village.




Figure 5: Cumulative hazard for clinical *P. falciparum* episodes in village TOT by A.) neighborhood MDA adherence, B.) household clustering of clinical *P. falciparum* episodes. C.) Indicates the human biting rate (HBR) for primary vectors by study month.




Table 1: Mixed effects logistic regression for odds of having a clinical *P. falciparum* episode (left panel, village TOT only) or clinical *P. vivax* episode (right panel, all four study villages). The models included a random intercept for individual participants, with repeat observations occurring within individuals over the study period.

covariate	<i>P. falciparum</i>		<i>P. vivax</i>	
	AOR	p-value	AOR	p-value
0 to 4	comparison		comparison	
5 to 14	3.0 (1.17 - 7.90)	0.0222	1.0 (0.40 - 2.32)	0.9433
15 plus	1.9 (0.73 - 4.72)	0.1979	0.4 (0.17 - 0.99)	0.0484
female	comparison		comparison	
male	1.2 (0.65 - 2.08)	0.6201	0.8 (0.41 - 1.53)	0.4790
no house member with clinical episode	comparison		comparison	
house member with clinical episode	4.2 (2.05 - 8.60)	< 0.0001	5.8 (3.39 - 9.93)	< 0.0001
doses of MDA complete	0.9 (0.82 - 1.07)	0.3320	1.1 (0.90 - 1.28)	0.4183
low MDA	comparison		comparison	
mid MDA	0.4 (0.12 - 1.06)	0.0630	0.8 (0.16 - 3.61)	0.7237
high MDA	0.1 (0.01 - 0.57)	0.0100	0.5 (0.05 - 5.85)	0.6028
low HBR	comparison		comparison	
mid HBR	1.0 (0.42 - 2.33)	0.9747	1.6 (1.07 - 2.40)	0.0210
high HBR	2.3 (1.17 - 4.46)	0.0153	1.6 (1.10 - 2.40)	0.0147
KNH			comparison	
TPN			0.6 (0.19 - 1.80)	0.3450
HKT			0.3 (0.05 - 1.52)	0.1377
TOT			0.7 (0.14 - 4.03)	0.7275

Study month was included as a control (a linear specification was used, but polynomial specifications were also tested). An interaction between individual level MDA adherence and neighborhood level adherence was also included as a control.

The human biting rate (HBR) was operationalized as a time-varying covariate with a one month lag. The covariate for having a house member with a clinical episode was also operationalized as a time-varying covariate (coded as “1” for any month in which another house member had a clinical *P. falciparum* episode and a “0” if no other house members had a clinical episode during that month.)

Table 2: Logistic regression for the odds of having a uPCR detected *P. falciparum* (left panel) or *P. vivax* infection (right panel) after MDA. Individuals in the data were coded as having an infection of either species if they were ever determined by uPCR to have an infection through blood screenings in full village blood surveys after MDA. Almost all *P. falciparum* episodes occurred in a single village (TOT) and the analysis for *P. falciparum* was only conducted on data from that village.

covariate	<i>P. falciparum</i>		<i>P. vivax</i>	
	AOR	p-value	AOR	p-value
0 to 4	comparison		comparison	
5 to 14	4.8 (0.85 - 89.92)	0.1451	2.6 (1.74 - 4.08)	< 0.0001
15 plus	4.9 (0.96 - 90.57)	0.1273	2.3 (1.57 - 3.57)	< 0.0001
female	comparison		comparison	
male	1.2 (0.55 - 2.57)	0.6748	1.8 (1.42 - 2.24)	< 0.0001
no clinical episode	comparison		comparison	
clinical episode	4.6 (1.83 - 11.05)	0.0008	2.7 (1.85 - 3.94)	< 0.0001
no house member with uPCR infection	comparison		comparison	
house member with uPCR infection	1.2 (0.45 - 2.87)	0.7226	1.5 (1.17 - 1.98)	0.0017
no house member with clinical episode	comparison		comparison	
house member with clinical episode	1.4 (0.58 - 3.23)	0.4518	1.2 (0.96 - 1.58)	0.0991
doses of MDA complete	0.9 (0.65 - 1.00)	0.2470	0.9 (0.88 - 1.01)	0.1160
low MDA	comparison		comparison	
mid MDA	0.4 (0.09 - 1.55)	0.2159	1.1 (0.67 - 1.82)	0.7083
high MDA	0.4 (0.08 - 1.65)	0.2407	1.5 (0.70 - 3.15)	0.2983
KNH			comparison	
TPN			1.1 (0.71 - 1.58)	0.7866
HKT			1.3 (0.75 - 2.38)	0.3284
TOT			5.2 (2.84 - 9.54)	< 0.0001

The number of surveys that an individual participated in was included as a control variable. An interaction control variable for individual level MDA adherence and neighborhood adherence was also included in the models.

Supplementary Table 1: Tertiles (lower, middle and upper 1/3) of MDA non-adherence (% taking no rounds of MDA) and HBR by all villages (used in regression for *P. vivax*) and for TOT alone (used in regression for *P. falciparum*)

	All villages	TOT only
high MDA	≥ 0.27	≥ 0.294
mid MDA	≥ 0.10 & < 0.27	≥ 0.20 & < 0.294
low MDA	< 0.10	< 0.20
high HBR	≥ 1.94	≥ 3.70
mid HBR	≥ 0.42 & < 1.94	≥ 0.36 & < 3.70
low HBR	< 0.42	< 0.36

Supplementary Figure 1: Spatial clusters (detecting using SatScan) of non-participation in MDA

